Comparative risk of Clostridioides difficile infection in patients with Crohn’s disease receiving ustekinumab versus anti-TNF therapy: a retrospective cohort study
Therapeutic Advances in Gastroenterology
Published online on February 16, 2026
Abstract
Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Background:Antitumor necrosis factor (anti-TNF) agents are associated with an increased risk ofClostridioides difficile(C. difficile) infection (CDI). The risk associated with Ustekinumab (UST) in real-world clinical practice remains poorly defined....
Background:Antitumor necrosis factor (anti-TNF) agents are associated with an increased risk ofClostridioides difficile(C. difficile) infection (CDI). The risk associated with Ustekinumab (UST) in real-world clinical practice remains poorly defined....